Jelena
Roganovic
https://orcid.org/0000-0002-7960-6069
REFERENCES
1. Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P.
Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors,
and Treatment. Cancers (Basel) . 2018;10(10):380.
2. Fernandes CJ, Morinaga LTK, Alves JL Jr, et al. Cancer-associated
thrombosis: the when, how and why. Eur Respir Rev.2019;28(151):180119.
3. Ko RH, Thornburg CD. Venous Thromboembolism in Children with Cancer
and Blood Disorders. Front Pediatr . 2017;5:12.
4. Athale UH, Yang JYK, Chan AKC. Thromboembolism in children with
cancer. In: UpToDate, Pappo AS, O’Brien S (Eds), UpToDate, Waltham, MA.
(Last updated on May 17, 2021; Accessed on February 02, 2022.)
5. Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in
venous thromboembolism in children’s hospitals in the United States from
2001 to 2007. Pediatrics. 2009;124(4):1001-1008.
6. Barg AA, Kenet G. Cancer-associated thrombosis in pediatric patients.Thromb Res. 2020;191 Suppl 1:S22-S25.
7. Kujovich JL. GeneReviews. Seattle (WA): University of Washington,
Seattle; 2018. Factor V Leiden thrombophilia.
8. Kujovich JL. GeneReviews. Seattle (WA): University of Washington,
Seattle; 2006. Prothrombin-related thrombophilia.
9. Rosenson RS, Smith CC, Bauer KA. Overview of homocysteine. In:
UpToDate, Freeman MW (Ed), UpToDate, Waltham, MA. (Last updated on
December 06, 2021; Accessed on February 21, 2022.)
10. Alfirevic Z, Simundic AM, Nikolac N, et al. of factor II G20210A,
factor V Leiden, MTHFR C677T and PAI-1 5G/4G polymorphism in patients
with venous thromboembolism: Croatian case-control study. Bioch
Med. 2010;20(2):229-235.
11. Coen D, Zadro R, Honovic L, Banfic L, Stavljenic Rukavina A.
Prevalence and association of the factor V Leiden and prothrombin
G20210A in healthy subjects and patients with venous thromboembolism.Croat Med J. 2001;42(4):488-492.
12. Akin DF, Sipahi K, Kayaalp T, et al. Factor V Leiden and prothrombin
20210A mutations among Turkish pediatric leukemia patients. Leuk
Res Treatment. 2012;2012:345-349.
13. Nowak-Göttl U, Wermes C, Junker R, et al. Prospective evaluation of
the thrombotic risk in children with ALL carrying the MTHFR TT 677
genotype, the prothrombin G20210A variant, and further prothrombotic
risk factors. Blood. 1999;93(5):1595-1599.
14. Elhasid R, Lanir N, Sharon R, et al. Prophylactic therapy with
enoxaparin during L-asparaginase treatment in children with ALL.Blood Coagul Fibrinolysis. 2001;12(5):367-70.
15. Pihusch R, Danzl G, Scholz M, et al. Impact of thrombophilic gene
mutations on thrombosis risk in patients with gastrointestinal
carcinoma. Cancer. 2002;94(12):3120-3126.
16. Eroglu A, Ulu A, Cam R, Kurtman C, Akar N. Prevalence of Factor V
1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of
venous thrombosis among cancer patients. J Thromb Thrombolysis.2007;23(1):31-34.
17. Battistelli S, Stefanoni M, Genovese A, Vittoria A, Cappelli R,
Roviello F. Prevalence of factor V Leiden and prothrombin G20210A in
patients with gastric cancer. World J Gastroenterol.2006;12(26):4179-4180.
18. Vossen CY, Hoffmeister M, Chang-Claude JC, Rosendaal FR, Brenner H.
Clotting factor gene polymorphisms and colorectal cancer risk. J
Clin Oncol. 2011;29(13):1722-1727.
19. Paspatis GA, Sfyridaki N, Papanikolaou N, et al. Resistance to
activated protein C, Factor V Leiden and the prothrombin G20210A variant
in patients with colorectal cancer. Pathophysiol Haemost Thromb.2002;32:2-7.
20. Martinelli I, Ponziani FR, Maino A, et al Thrombosis after liver
transplantation for hepatocellular carcinoma. PLoS One.2017;12(10):e0186699.
21. Albisetti M, Chan AKC. Venous thrombosis and thromboembolism (VTE)
in children: Risk factors, clinical manifestations, and diagnosis. In:
UpToDate, O’Brien S (Ed), UpToDate, Waltham, MA. (Last updated on
February 03, 2022; Accessed on February 12, 2022.)
22. Tuckuviene R, Christensen AL, Helgestad J, Johnsen SP, Kristensen
SR. Pediatric venous and arterial noncerebral thromboembolism in
Denmark: a nationwide population-based study. J Pediatr.2011;159(4):663-669.
23. Takemoto CM, Sohi S, Desai K, et al. Hospital-associated venous
thromboembolism in children: incidence and clinical characteristics.J Pediatr. 2014;164(2):332-338.
24. Giordano P, Grassi M, Saracco P, et al; Paediatric Thrombosis
Working Group of the RITI. Paediatric venous thromboembolism: a report
from the Italian Registry of Thrombosis in Children (RITI). Blood
Transfus. 2018;16(4):363-370.
25. Jinks S, Arana A. Venous thromboembolism in paediatrics. BJA
Educ. 2019;19(9):305-312.
26. Athale UH, Chan AK. Thromboembolic complications in pediatric
hematologic malignancies. Semin Thromb Hemost.2007;33(4):416-426.
27. Lipay NV, Zmitrovich AI, Aleinikova OV. Epidemiology of venous
thromboembolism in children with malignant diseases: a single-center
study of the Belarusian Center for Pediatric Oncology and Hematology.Thromb Res. 2011;128(2):130–134.
28. Athale U, Siciliano S, Thabane L, et al. Epidemiology and clinical
risk factors predisposing to thromboembolism in children with cancer.Pediatr Blood Cancer. 2008;51(6):792-797.
29. Pelland-Marcotte MC, Pole JD, Kulkarni K, et al. Thromboembolism
Incidence and Risk Factors in Children with Cancer: A Population-Based
Cohort Study. Thromb Haemost. 2018;118(9):1646-1655.
30. Athale U, Cox S, Siciliano S, Chan AK. Thromboembolism in children
with sarcoma. Pediatr Blood Cancer. 2007;49(2):171-176.
31. Schiavetti A, Foco M, Ingrosso A, Bonci E, Conti L, Matrunola M.
Venous thrombosis in children with solid tumors. J Pediatr Hematol
Oncol. 2008;30(2):148-152.
32. Paz-Priel I, Long L, Helman LJ, Mackall CL, Wayne AS. Thromboembolic
events in children and young adults with pediatric sarcoma. J Clin
Oncol. 2007;25(12):1519-1524.
33. Piovesan D, Attard C, Monagle P, Ignjatovic V. Epidemiology of
venous thrombosis in children with cancer. Thromb Haemost.2014;111:1015–1021.
34. Athale UH, Nagel K, Khan AA, Chan AK. Thromboembolism in children
with lymphoma. Thromb Res. 2008;122(4):459-465.
35. Tabori U, Beni-Adani L, Dvir R, et al. Risk of venous
thromboembolism in pediatric patients with brain tumors. Pediatr
Blood Cancer. 2004;43(6):633-636.
36. Castle J, Blower E, Kirwan CC. Update on the role of circulating
tumour cells in cancer-associated thrombosis. Thrombosis Update.2021;5:100066.
37. Rubio-Jurado B, Sosa-Quintero LS, Guzmán-Silahua S, García-Luna E,
Riebeling-Navarro C, Nava-Zavala AH. The prothrombotic state in cancer.Adv Clin Chem. 2021;105:213-242.
38. Spavor M, Halton J, Dietrich K, et al. Age at cancer diagnosis,
non-O blood group and asparaginase therapy are independently associated
with deep venous thrombosis in pediatric oncology patients: A risk
model. Thromb Res. 2016;144:27-31.
39. Prasca S, Carmona R, Ji L, et al. Obesity and risk for venous
thromboembolism from contemporary therapy for pediatric ALL.Thromb Res. 2018;165:44-50.
40. Caruso V, Iacoviello L, Di Castelnuovo A, et al. Thrombotic
complications in childhood ALL: a meta-analysis of 17 prospective
studies comprising 1752 pediatric patients. Blood.2006;108(7):2216-2222.
41. Athale U. Thrombosis in pediatric cancer: identifying the risk
factors to improve care. Semin Thromb Hemost. 2007;33(4):416-426.
42. Albisetti M, Kellenberger CJ, Bergsträsser E, et al.
Port-a-cath-related thrombosis and postthrombotic syndrome in pediatric
oncology patients. J Pediatr. 2013;163(5):1340-1346.
43. Wiegering V, Schmid S, Andres O, et al. Thrombosis as a complication
of central venous access in pediatric patients with malignancies: a
5-year single-center experience. BMC Hematol. 2014;14(1):18.
44. Dentali F, Gianni M, Agnelli G, Ageno W. Association between
inherited thrombophilic abnormalities and central venous catheter
thrombosis in patients with cancer: a meta-analysis. J Thromb
Haemost. 2008;6(1):70-75.
45. Schoot RA, van de Wetering MD, et al; DCOG-Aristocaths Supportive
Care Working Group. Prevalence of Symptomatic and Asymptomatic
Thrombosis in Pediatric Oncology Patients With Tunneled Central Venous
Catheters. Pediatr Blood Cancer. 2016;63(8):1438-1444.
46. Musgrave KM, van Delft FW, Avery PJ, et al. Cerebral sinovenous
thrombosis in children and young adults with acute lymphoblastic
leukaemia – a cohort study from the United Kingdom. Br J
Haematol. 2017;179(4):667-669.
47. Ranta S, Tuckuviene R, Mäkipernaa A, et al. Cerebral sinus venous
thromboses in children with acute lymphoblastic leukaemia - a
multicentre study from the Nordic Society of Paediatric Haematology and
Oncology. Br J Haematol. 2015;168(4):547-552.
48. Ghanem KM, Dhayni RM, Al-Aridi C, et al. Cerebral sinus venous
thrombosis during childhood ALL therapy: Risk factors and management.Pediatr Blood Cancer. 2017;64(12):e26694.
49. El-Khoury H, Saifi O, Haddad S, et al. Treatment-induced cerebral
sinus venous thrombosis in childhood acute lymphoblastic malignancies:
New risk factors to consider. Pediatr Blood Cancer.2021;68(11):e29210.
50. Athale UH, Chan AK. Thrombosis in children with ALL: part I.
Epidemiology of thrombosis in children with ALL. Thromb Res.2003;111(3):125-131.
51. Decousus H, Moulin N, Quenet S, et al. Thrombophilia and risk of
venous thrombosis in patients with cancer. Thromb Res. 2007;120
Suppl 2:S51-61.
52. Horowitz N, Brenner B. Thrombophilia and cancer. Pathophysiol
Haemost Thromb. 2008;36(3-4):131-136.
53. Khan S, Dickerman JD. Hereditary thrombophilia. Thromb J.2006;4:15.
54. Knöfler R, Siegert E, Lauterbach I, et al. Clinical importance of
prothrombotic risk factors in pediatric patients with
malignancy–impact of central venous lines. Eur J Pediatr.1999;158 Suppl 3:S147-150.
55. Ünal S, Varan A, Yalçin B, Büyükpamukçu M, Gürgey A. Evaluation of
thrombotic children with malignancy. Ann Hematol.2005;84(6):395-399.
56. Barzilai-Birenboim S, Nirel R, Arad-Cohen N, et al. Venous
Thromboembolism and Its Risk Factors in Children with ALL in Israel: A
Population-Based Study. Cancers (Basel). 2020;12(10):2759.
57. Sifontes MT, Nuss R, Hunger SP, Wilimas J, Jacobson LJ,
Manco-Johnson MJ. The factor V Leiden mutation in children with cancer
and thrombosis. Br J Haematol . 1997;96(3):484-489.
58. Ruud E, Holmstrøm H, Natvig S, Wesenberg F. Prevalence of
thrombophilia and central venous catheter-associated neck vein
thrombosis in 41 children with cancer–a prospective study. Med
Pediatr Oncol. 2002;38(6):405-410.
59. Mauz-Korholz C, Junker R, Gobel U, Nowak-Gottl U. Prothrombotic risk
factors in children with ALL treated with delayed E. coli asparaginase
(COALL-92 and 97 protocols). Thromb Haemost. 2000;83(6):840-843.
60. Mitchell LG, Andrew M, Hanna K, et al; Prophylactic Antithrombin
Replacement in Kids with ALL Treated with Asparaginase Group (PARKAA). A
prospective cohort study determining the prevalence of thrombotic events
in children with ALL and a central venous line who are treated with
L-asparaginase: results of the Prophylactic Antithrombin Replacement in
Kids with ALL Treated with Asparaginase (PARKAA) Study. Cancer.2003;97(2):508-516.